Kyverna Therapeutics Inc., a clinical-stage biopharmaceutical company, reported its financial results for the quarter ended March 31, 2025. The company announced a net loss of $44.6 million, or a net loss per common share of $1.03, compared to a net loss of $26.7 million, or a net loss per common share of $1.12, for the same period in 2024. Research and Development (R&D) expenses increased to $37.4 million for the quarter, up from $22.5 million in the corresponding quarter of the previous year. General and Administrative (G&A) expenses also rose to $10.0 million from $6.9 million year-over-year. The company reported having $242.6 million in cash, cash equivalents, and available-for-sale marketable securities as of March 31, 2025, providing a cash runway into 2027. This financial position supports Kyverna's first Biologics License Application $(BLA.AU)$ filing and the Phase 3 trial for myasthenia gravis $(MG)$, along with pre-launch activities. Operationally, Kyverna has completed enrollment in its registrational Phase 2 KYV-101 trial for stiff person syndrome (SPS), with topline data expected in the first half of 2026. Following a successful end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), the company is advancing to a registrational Phase 3 trial for KYV-101 in myasthenia gravis (MG), with Phase 2 data anticipated in the second half of 2025. Additionally, Kyverna plans to host a Key Opinion Leader $(KOL)$ event in the third quarter of 2025, highlighting its neuroinflammation franchise.